ASXNotice of Annual General Meeting/Proxy Form
other announcement
RCE
Recce Pharmaceuticals
Pharmaceuticals, Biotechnology & Life Sciences
Recce Pharmaceuticals Ltd is an Australian pharmaceutical company focused on developing a new class of synthetic anti-infectives to combat antibiotic-resistant superbugs. Their lead candidate, RECCE® 327, has received Qualified Infectious Disease Product (QIDP) designation from the FDA, offering potential market exclusivity. The company aims to provide effective treatments against a broad range of bacteria and viral indications.
Short position
short percentage0.00%
reported shorts4.3K
shares on issue305.770M
Recce Pharmaceuticals (ASX:RCE) has 0.00% of its shares on issue reported as short positions as of 5 Oct 2026, or about 4,267 shares. Over the past 30 days that figure has been broadly flat, and over 90 days it has been broadly flat. Its highest recorded short interest was 0.37% in August 2021. RCE is classified in the Pharmaceuticals, Biotechnology & Life Sciences industry. All figures come from official ASIC short position reports, published with a four trading-day (T+4) delay.
Price & short interest
Toggle series, zoom, and compare · ASIC daily, T+4Recce Pharmaceuticals (RCE) News
Latest articles and price-sensitive announcements with AI sentiment classification.
Notification of cessation of securities - RCE
other announcement
Resolutions under section 249N of the Corporations Act
other announcement
Small Caps
StockheadRecce approval has R327G go head-to-head with antibiotic treatments
Recce has received ethics approval for an amendment to its pivotal Phase III Australian trial of R327G for treating diabetic ... Read More The post Recce approval has R327G go head-to-head with antibiotic treatments appeared first on Stockhead.
HREC Approves Comparator Study for Pivotal Phase 3 DFI
other announcement
Change of Director's Interest Notices (x4)
director_dealing announcement
KalkineRecce Pharmaceuticals Files Cleansing Notice After Issuing 250,000 Shares on July 31, 2026
Recce Pharmaceuticals Ltd (ASX:RCE) has submitted a cleansing notice under section 708A(5)(e) of the Corporations Act 2001, following the issuance of 250,000 fully paid ordinary shares on 31 July 2026. Key Highlights Recce Pharmaceuticals issued 250,000 fully paid ordinary shares on 31 July 2026 The shares were issued without investor disclosure under Part 6D.2 of the Corporations Act The company confirms compliance with Chapter 2M and sections 674 and 674A of the Corporations Act No excluded...
Google NewsRecce Pharmaceuticals Issues 250,000 Shares at $0.375 Each for Corporate Advisory Services - Kalkine
Recce Pharmaceuticals Issues 250,000 Shares at $0.375 Each for Corporate Advisory Services Kalkine
US$66.9bn biodefence plan welcomed by superbug fighter Recce
Recce Pharmaceuticals has welcomed the release of a five-year, US$66.9 billion medical countermeasures funding strategy by the US Government. ... Read More The post US$66.9bn biodefence plan welcomed by superbug fighter Recce appeared first on Stockhead.
Completion of Share Purchase Plan and Shortfall Notice
capital_raise announcement
U.S. Government Releases US$66.9B AMR Biodefense Strategy
other announcement
Quarterly Activities/Appendix 4C Cash Flow Report
other announcement
Investor Webinar - Q4 FY26 Investor Presentation Deck
other announcement
Recce Pharmaceuticals (ASX:RCE): Share Purchase Plan Deadline Extended---What Investors Need to Know - Kalkine
Recce Pharmaceuticals (ASX:RCE): Share Purchase Plan Deadline Extended---What Investors Need to Know Kalkine
Extension to Share Purchase Plan Closing Date
capital_raise announcement
ASX Today: Why Recce Pharmaceuticals (ASX:RCE) Shares Are Gaining - Kalkine
ASX Today: Why Recce Pharmaceuticals (ASX:RCE) Shares Are Gaining Kalkine
Why Recce Pharmaceuticals (ASX:RCE) Is Expanding Its ASEAN Footprint
Highlights Vietnam patent strengthens Recces intellectual property portfolio. ASEAN strategy gains support through broader regional protection. Clinical, regulatory and licensing activities continue to advance. Recce Pharmaceuticals has expanded its intellectual property footprint with a newly granted Vietnam patent covering key anti-infective candidates. The development supports the company's long-term ASEAN strategy, complements ongoing clinical programs, and reinforces efforts to advance r...
Recce strengthens IP for anti-infectives with Vietnamese patent grant
Expiring in 2041, the patent covers preparation and use of RCE's synthetic anti-infectives across a range of potential applications ... Read More The post Recce strengthens IP for anti-infectives with Vietnamese patent grant appeared first on Stockhead.
Vietnamese Patent Granted for RECCE Anti-Infectives
other announcement
Share Purchase Plan - Letter and Offer Booklet
capital_raise announcement
HREC Approval Accelerates Global Phase 3 DFI Strategy
other announcement
Recce Pharmaceuticals Gains Momentum Amid Strong Insider Confidence
Highlights Insider activity has strengthened market confidence Recce Pharmaceuticals continues attracting investor attention Strong ownership alignment supports long-term outlook Recce Pharmaceuticals has emerged as a notable healthcare sector story after strong market momentum and continued insider participation highlighted growing confidence around the company’s future direction. Australian biotechnology company Recce Pharmaceuticals (ASX:RCE) has recently captured broader marke...
Recce Pharmaceuticals Expands Reach Across MENA Healthcare Markets
Highlights Recce expands focus across key MENA healthcare markets R327 Topical Gel targets diabetic foot infections Manufacturing readiness supports regional growth plans Recce Pharmaceuticals is advancing its regional healthcare footprint through a long-term MENA licensing arrangement focused on diabetic foot infections, strengthening attention on infection management and pharmaceutical innovation. Recce Pharmaceuticals Ltd (ASX:RCE) has attracted fresh market attention following the a...
Addendum to Recce Signs Middle East Licensing Term Sheet
other announcement
Why Is Recce Pharma’s Indonesia Milestone Gaining Attention?
Highlights Regulatory inspection completed with no changes required Clinical trial progress continues without disruption Strategic pathway strengthens expansion plans Recce Pharmaceuticals advances its clinical journey after a successful regulatory inspection in Indonesia, reinforcing confidence in its ongoing study and supporting broader regional expansion ambitions. Recce Pharmaceuticals (ASX:RCE) has marked a significant step forward in its clinical development journey, drawing atten...
Positive Regulatory Inspection Outcome for Phase 3 Trial
other announcement